PRECISION BIOSCIENCES INC

Item 5. Other Information.

Rule 10b5-1 Trading Plans

On January 13, 2025, Jeff Smith, our Chief Research Officer, entered into a trading plan intended to satisfy the affirmative defense conditions under Rule 10b5-1(c). Dr. Smith’s trading plan provides for the sale of, in the aggregate, up to 7,931 shares of our common stock from May 8, 2025 through January 8, 2026, unless the plan is earlier terminated. This represents the maximum number of shares that may be sold pursuant to Dr. Smith’s Rule 10b5-1 plan. The actual number of shares sold will be dependent on the satisfaction of certain conditions set forth in the written plan.

On January 17, 2025, Alex Kelly, our Chief Financial Officer, entered into a sell-to-cover instruction letter intended to satisfy the affirmative defense conditions under Rule 10b5-1(c). Mr. Kelly’s instruction letter provides for sales of such number of shares of our common stock as are necessary to satisfy the applicable tax withholding obligations arising from the vesting of Restricted Stock Units granted to him. The total number of shares that may be sold pursuant to the sell-to-cover instruction letter is not determinable. Mr. Kelly’s instruction letter may only be modified, terminated or amended by a signed writing provided by Mr. Kelly during an open trading window under the Company’s insider trading policies.